https://doi.org/10.4081/reumatismo.2021.1312
Does human serotonin-1A receptor polymorphism (rs6295) code for pain and associated symptoms in fibromyalgia syndrome?
Submitted: 25 June 2020
Accepted: 23 February 2021
Published: 19 April 2021
Accepted: 23 February 2021
Abstract Views: 3609
PDF: 614
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Genetic predisposition may play an important role in the development of fibromyalgia syndrome (FMS). Serotonin is known to be involved in pain modulation and serotonin-1A receptor plays a considerable role in determining the central 5-HT tone. Consequently, variation in 5-HT1A receptor gene (HTR1A) may be responsible for inter-individual variability in pain sensitivity and other clinical symptoms of FMS. Therefore, the objectives of this research work were to study the gene polymorphism of 5-HTR1A gene and to explore the correlation between rs6295 genotype (−1019C/G HTR1A) and duration of pain, pain intensity and pain related depression and anxiety, if any, in FMS. 5-HTR1A genotype for the C(-1019)G polymorphism was typed in 62 patients with FMS and 42 healthy subjects. Present pain intensity, components of pain and pain related depression and anxiety were assessed using the numerical pain rating scale, McGill pain questionnaire and Hamilton depression and anxiety rating scale respectively. 5-HTR1A gene was represented by three different genotypes, homozygous C/C, heterozygous C/G and homozygous G/G. Analysis of the 5-HTR1A gene showed a frequency of 58%, 31% and 11% for the C/C, C/G and G/G genotypes, respectively in FMS group. This proportion was 69%, 23% and 8% in healthy subjects. No significant correlation was observed between 5-HTR1A gene polymorphism and pain and related symptoms in FMS patients. To the best of our knowledge this is the first study which investigated the correlation between the 5-HTR1A gene polymorphism and pain intensity, the affective component of pain, pain related depression and anxiety in FMS.
Son CN, Kim SH, Chang HW, Kim JM. A neurometabolite study of chronic daily headache in patients with systemic lupus erythematosus using magnetic resonance spectroscopy: comparison with fibromyalgia patients and healthy controls. Korean J Intern Med. 2016; 31: 1171-7.
DOI: https://doi.org/10.3904/kjim.2015.196
Buskila, D, Sarzi-Puttini, P, Ablin, JN. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007; 8: 67-74.
DOI: https://doi.org/10.2217/14622416.8.1.67
Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992; 35: 550-6.
DOI: https://doi.org/10.1002/art.1780350509
Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiat. 1998; 44: 151-62.
DOI: https://doi.org/10.1016/S0006-3223(98)00139-5
Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003; 23:8788-99.
DOI: https://doi.org/10.1523/JNEUROSCI.23-25-08788.2003
Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999; 38: 1083-152.
DOI: https://doi.org/10.1016/S0028-3908(99)00010-6
Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry. 1979; 136: 1184-7.
DOI: https://doi.org/10.1176/ajp.136.9.1184
Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience. 2010; 166: 1023-35.
DOI: https://doi.org/10.1016/j.neuroscience.2010.01.036
Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a (carbonyl-C-11)WAY100635 positron emission tomography study. Biol Psychiatry. 2006; 59: 106-13.
DOI: https://doi.org/10.1016/j.biopsych.2005.06.016
Sullivan GM, Ogden RT, Oquendo MA, et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry. 2009; 66: 223-30.
DOI: https://doi.org/10.1016/j.biopsych.2009.01.028
Lanzenberger RR, Mitterhauser M, Spindelegger C, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry. 2007; 61: 1081-9.
DOI: https://doi.org/10.1016/j.biopsych.2006.05.022
Cohn JB, Rickels K. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin. 1989; 11: 304-20.
DOI: https://doi.org/10.1185/03007998909115213
Wang SM, Han C, Lee SJ, et al. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013; 17: 160-9.
DOI: https://doi.org/10.3109/13651501.2013.794245
Lemonde S, Du L, Bakish D, et al. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol. 2004; 7: 501-6.
DOI: https://doi.org/10.1017/S1461145704004699
Malaguti A, Rossini D, Lucca A, et al. Role of COMT, 5-HT(1A), and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation. Depress Anxiety. 2011; 28: 568-73.
DOI: https://doi.org/10.1002/da.20815
Huang YY, Battistuzzi C, Oquendo MA, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. IntJ Neuropsychopharmacol. 2004; 7: 441-51.
DOI: https://doi.org/10.1017/S1461145704004663
Clauw DJ. Fibromyalgia: an overview. Am J Med. 2009; 122: S3-S13.
DOI: https://doi.org/10.1016/j.amjmed.2009.09.006
Ruoff GE. Depression in the patient with chronic pain. J Fam Pract. 1996; 43: S25-34.
Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum. 1990; 33: 160-72.
DOI: https://doi.org/10.1002/art.1780330203
Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain. 1993; 55: 195-203.
DOI: https://doi.org/10.1016/0304-3959(93)90148-I
Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain. 1975; 1: 277-99.
DOI: https://doi.org/10.1016/0304-3959(75)90044-5
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32: 50-5.
DOI: https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
Koller G, Bondy B, Preuss UW, et al. The C(−1019)G 5-HT1A promoter polymorphism and personality traits: No evidence for significant association in alcoholic patients. Behav Brain Funct. 2006; 2: 7.
DOI: https://doi.org/10.1186/1744-9081-2-7
Hamilton, MJ. A rating scale for depression. Neurology Neurosurgery and Psychiatr. 1960; 23: 56-62.
DOI: https://doi.org/10.1136/jnnp.23.1.56
Ablin JN, Bar-Shira A, Yaron M, Orr-Urtreger A. Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. Clin Exp Rheumatol. 2009; 27: S33-8.
Lebe M, Hasenbring MI, Schmieder K, et al. Association of serotonin-1A and -2A receptor promoter polymorphisms with depressive symptoms, functional recovery, and pain in patients 6 months after lumbar disc surgery. Pain. 2013; 154: 377-84.
DOI: https://doi.org/10.1016/j.pain.2012.11.017
Ueda H, Neyama H. LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress, empathy. Neurobiol Pain. 2017; 1: 16-25.
DOI: https://doi.org/10.1016/j.ynpai.2017.04.002
Potvin S, Larouche A, Normand E, et al. No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls. Eur J Pain 2010; 14: 742-6.
DOI: https://doi.org/10.1016/j.ejpain.2009.12.004
Riering K, Rewerts C, Zieglgänsberger W. Analgesic effects of 5‐HT3 receptor antagonists. Scand J Rheumatol. 2004; 33: 19-23.
DOI: https://doi.org/10.1080/03009740410006970
Bondy, B, Spaeth, M, Offenbaecher, M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis.1999; 6: 433-9.
DOI: https://doi.org/10.1006/nbdi.1999.0262
Tander B, Gunes S, Boke O, et al. Polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase genes: a study on fibromyalgia susceptibility. Rheumatol Int. 2008; 28: 685-91.
DOI: https://doi.org/10.1007/s00296-008-0525-8
Tour J, Löfgren M, Mannerkorpi K, et al. Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls - antagonistic effects between opioid and serotonin-related genes. Pain. 2017; 158: 1194-203.
DOI: https://doi.org/10.1097/j.pain.0000000000000896
Xiao Y, Russell IJ, Liu YG. A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein. Rheumatol Int. 2012; 32: 2479-85.
DOI: https://doi.org/10.1007/s00296-011-1990-z
How to Cite
Tanwar, S., Mattoo, B., Kumar, U., Dada, R., & Bhatia, R. (2021). Does human serotonin-1A receptor polymorphism (rs6295) code for pain and associated symptoms in fibromyalgia syndrome?. Reumatismo, 73(1), 24–31. https://doi.org/10.4081/reumatismo.2021.1312
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- M. Colaci, D. Giuggioli, M. Sebastiani, A. Manfredi, F. Lumetti, F. Luppi, S. Cerri, C. Ferri, Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline , Reumatismo: Vol. 67 No. 4 (2015)
- L. Riente, The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- M. Rossini, D. Gatti, O. Viapiana, C. Caimmi, L. Idolazzi, E. Fracassi, S. Adami, Vitamin D and rheumatic diseases , Reumatismo: Vol. 66 No. 2 (2014)
- D. Gatti, O. Viapiana, G. Colombo, S. Adami, How much does an antiinflammatory treatment cost? , Reumatismo: Vol. 62 No. 4 (2010)
- S. Warwas, C. Specker, M. Jäger, S. Landgraeber, Arthroscopic synovectomy and radiosynoviorthesis: a treatment option for recurrent arthritis symptoms in patients with pachydermoperiostosis , Reumatismo: Vol. 65 No. 2 (2013)
- E. Filippucci, A. Farina, F. Bartolucci, C. Spallacci, P. Busilacchi, W. Grassi, Fluoroquinolone-induced bilateral rupture of the Achilles tendon: clinical and sonographic findings , Reumatismo: Vol. 55 No. 4 (2003)
- L. Degli Esposti, V. Perrone, D. Sangiorgi, L. Sinigaglia, Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs , Reumatismo: Vol. 73 No. 1 (2021)
- C. Garufi, S. Mancuso, F. Ceccarelli, L. Caruso, C. Alessandri, M. Di Franco, R. Priori, V. Riccieri, R. Scrivo, S. Truglia, F. Conti, F.R. Spinelli, PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors , Reumatismo: Early Access
- T. Suzuki, H. Shirai, Subcalcaneal bursitis as the initial manifestation of rheumatoid arthritis: ultrasonographic observation of two cases , Reumatismo: Vol. 71 No. 4 (2019)
- E. Lubrano, A. Spadaro, From rehabilitation to remission in ankylosing spondylitis , Reumatismo: Vol. 61 No. 4 (2009)
<< < 10 11 12 13 14 15 16 17 18 19 > >>
You may also start an advanced similarity search for this article.
